CVS HEALTH (NYSE:CVS) is reportedly close to striking an agreement to acquire Oak Street Health for approximately $10.5 billion, including debt. The two companies are discussing a price of about $39 per share, and the deal could be announced as early as this week.
CVS Health (NYSE:CVS) is close to a $10.5 billion deal to acquire Oak Street Read Post »
CVS Health (NYSE:CVS) Stock Price Trend Forecast and Trading Range： 2023.1.3 From the stock price chart analysis, today’s stock price opened low and continued to rise, closing unchanged from the previous trading day.Stock prices are in a downtrend in the short term, it is not recommended to buy and hold. The outlook for medium-term and long-term earnings is too uncertain and short-term returns are low. It is recommended to wait patiently for the right trading opportunity. From the analysis of financial statements, the revenue in the third quarter of fiscal 2022 was $81.159 billion, YoY +9.98%, net profit was -$3.416 billion, EPS was -$2.6. Quarterly dividend of $0.55 per share. The revenue loss was mainly due to compensation for a one-time loss, and adjusted earnings per share were 6% higher than the same period last year. The best medium to long term buying price is between $75-$85. (Note: The upper
CVS Health (NYSE:CVS) Stock Price Trend Forecast and Trading Range 2023.1.3 Read Post »
Evercore ISI analyst Elizabeth Anderson downgraded CVS Health (CVS) from outperform to be in line with the market, lowering its price target to $100 from $120. Anderson told investors in a research note that a channel check conducted during Medicare Advantage enrollment showed that CVS Health’s 2023 plan offerings were competitive. The analyst said that while the inspection results showed that the company’s Aetna was doing well in some regions, its share growth did not appear to be strong compared to previous years. Anderson believes CVS Health’s valuation in 2023 will bounce back in a relative range pending greater certainty in the final portfolio.
Evercore ISI Downgrades CVS Health to In-Line, Lowers Price Target to $100 Read Post »